Adenocarcinoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung ... - Dove Medical Press



Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung ... 
Dove Medical Press
... adenocarcinoma with a high tolerance by patients. In addition, pemetrexed maintenance therapy of advanced lung adenocarcinoma is safe and effective for the treatment of advanced lung adenocarcinoma following pemetrexed and nedaplatin combination ...

 


Treating Advanced Non-Driver Lung Adenocarcinoma - OncLive



OncLive
 
Treating Advanced Non-Driver Lung Adenocarcinoma 
OncLive
The approach to first-line treatment of advanced non?small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma. In the past decade, one of the first results with major clinical implications ...

 


Adenocarcinoma arising from a gastric duplication cyst: a case report and literature review - Dove Medical Press



Adenocarcinoma arising from a gastric duplication cyst: a case report and literature review 
Dove Medical Press
Biopsies of the mass edge reported the occurrence of moderately differentiated adenocarcinoma and mild chronic gastritis. Computed tomography imaging showed a 5.16.5 cm cystic mass in the gastric greater curvature. The patient received six cycles of ...

and more » 


F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy ... - Journal of Nuclear Medicine



F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy ... 
Journal of Nuclear Medicine
This study aimed to determine whether 18F-FDG PET response after induction chemotherapy before concurrent chemoradiotherapy can identify patients with esophageal adenocarcinoma who may benefit from subsequent esophagectomy. Methods: We ...

 


Why Keytruda Could Boost Merck's Revenue Growth in 2018 ... - Market Realist



Market Realist
 
Why Keytruda Could Boost Merck's Revenue Growth in 2018 ... 
Market Realist
In September 2017, the FDA approved Merck's (MRK) Keytruda for the treatment of individuals with relapsing or recurrent metastatic GEJ (gastroesophageal ...

and more » 


CDC: 40 percent of new cancers tied to being overweight - FOX 10 News Phoenix



FOX 10 News Phoenix
 
CDC: 40 percent of new cancers tied to being overweight 
FOX 10 News Phoenix
Then, in December of 2014, Pavuk was diagnosed with a type of esophageal cancer known as adenocarcinoma of the esophagus. It's one of 13 cancers, including liver, gall bladder, kidney, upper stomach, pancreas, and colon and rectal cancers, the Centers ...

and more » 


Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells - Dove Medical Press



Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells 
Dove Medical Press
Background: Colorectal signet ring cell (SRC) carcinoma occurs rarely with a poor prognosis. The present study assessed the prognostic factors and predictive value of SRC ratio in colorectal mucinous adenocarcinoma (MAC) with SRCs (MAC-SRC). Patients ...

 


The clinical significance of CXCL5 in non-small cell lung cancer - Dove Medical Press



The clinical significance of CXCL5 in non-small cell lung cancer 
Dove Medical Press
Elevated CXCL5 protein abundance predicted poor overall survival in adenocarcinoma patients. Further meta-analysis demonstrated that CXCL5 mRNA expression was also positively associated with tumor stage, lymph node metastasis, and worse survival.

 


Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer - Markets Insider



Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer 
Markets Insider
DESTINY-Gastric01 is a pivotal phase 2, open-label study investigating the safety and efficacy of DS-8201 in patients with HER2-expressing advanced gastric cancer or gastroesophageal junction adenocarcinoma (defined as IHC3+ or IHC2+/ISH+) who have ...

and more » 


Wider sampling of tumor tissues may guide drug choice, improve outcomes - Medical Xpress



Medical Xpress
 
Wider sampling of tumor tissues may guide drug choice, improve outcomes 
Medical Xpress
This is particularly the case for gastric and esophageal adenocarcinoma (GEA), which are common cancers. They can be difficult to control and are often detected and diagnosed late. They frequently recur after surgery, and those recurrences are ...

and more »